Evotec (NASDAQ:EVO) Shares Gap Up – Here’s Why

Posted by Brenda Bartman on Oct 16th, 2026

Evotec AG (NASDAQ:EVO – Get Free Report) shares gapped up before the market opened on Wednesday. The stock had previously closed at $1.3450, but opened at $1.48. Evotec shares last traded at $1.4550, with a volume of 52,919 shares traded.

Key Evotec News

Here are the key news stories impacting Evotec this week:

Positive Sentiment: Evotec reported preliminary nine-month revenue and adjusted EBITDA above market expectations, indicating that the company’s recovery may be gaining traction after a difficult period. The results prompted a favorable market reaction and improved confidence in its outlook. Evotec shares jump after preliminary 9-month revenue, EBITDA top estimates
Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $4.00 price target, implying substantial upside from recent trading levels. The target suggests the analyst expects the financial recovery and restructuring efforts to create significant value. HC Wainwright reaffirms buy rating
Positive Sentiment: Evotec appointed Dr. Joanna Holbrook as chief scientific officer and a member of the management board, effective November 1, 2026. The former Novo scientist brings more than 25 years of experience across pharmaceuticals, biotechnology and academia and will lead Evotec’s global scientific strategy, technology platforms and proprietary innovation. Her appointment could strengthen the company’s drug-discovery capabilities and differentiation. Evotec appoints Dr. Joanna Holbrook as chief scientific officer

Analyst Ratings Changes

Several analysts have commented on the stock. Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday, July 15th. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 25th. Finally, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Evotec in a report on Wednesday. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $3.00.

Read Our Latest Research Report on Evotec

Evotec Trading Down 0.4%

The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average is $1.75 and its 200 day moving average is $2.36.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Apollon Wealth Management LLC acquired a new stake in shares of Evotec during the 1st quarter valued at about $28,000. SmartHarvest Portfolios LLC purchased a new position in shares of Evotec in the 1st quarter valued at about $44,000. Optiver Holding B.V. raised its holdings in Evotec by 598.4% in the 1st quarter. Optiver Holding B.V. now owns 283,576 shares of the company’s stock worth $709,000 after purchasing an additional 242,973 shares during the period. Finally, WCM Investment Management LLC raised its holdings in Evotec by 12.1% in the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after purchasing an additional 67,917 shares during the period. Institutional investors and hedge funds own 5.81% of the company’s stock.

About Evotec

(Get Free Report)

Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Founded in 1993, the company supports programs from early-stage research through preclinical and clinical development, with expertise in small-molecule and biologic therapies.

Its activities include target identification and validation, screening, medicinal chemistry, pharmacology, drug manufacturing support and development services.